Drugs acting on the renin-angiotensin system and SARS-CoV-2.

Antonio Vitiello, Chiara Pelliccia, Francesco Ferrara

Drug discovery today 2021 Apr

filter terms:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the ongoing global Coronavirus 2019 (COVID-19) pandemic, resulting in thousands of deaths worldwide and representing a health challenge with few precedents in human history. Angiotensin-converting enzyme 2 (ACE-2) facilitates the access of SARS-CoV-2 to cells. Therapeutic agents acting on the renin-angiotensin system (RAS) might be able to modulate the concentration of ACE-2 and the various components of the system. Here, we discuss current pharmacological, molecular, and clinical evidence to investigate whether drugs acting on RAS with modulation of the ACE-2 concentration have added value in combating SARS-CoV-2 infection. We also highlight the possible deleterious action of the ACE/Ang-II/AT-1r axis and possible beneficial role of the ACE-2/Ang 1-7/MasR axis in acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2, discussing the possibility of addressing the various RAS components with drug treatments to improve clinical outcomes. Copyright © 2021 Elsevier Ltd. All rights reserved.

Citation

Antonio Vitiello, Chiara Pelliccia, Francesco Ferrara. Drugs acting on the renin-angiotensin system and SARS-CoV-2. Drug discovery today. 2021 Apr;26(4):870-874